Trials / Completed
CompletedNCT00856856
ABSORB Clinical Investigation, Cohort B
A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With de Novo Native Coronary Artery Lesions.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and performance of the BVS Everolimus Eluting Coronary Stent System (EECSS) in the treatment of patients with a maximum of two de novo native coronary artery lesions located in two different major epicardial vessels. Currently in development at Abbott Vascular. Not available for sale in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Bioabsorbable Everolimus Eluting Coronary Stent | Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2015-10-01
- Completion
- 2016-03-01
- First posted
- 2009-03-06
- Last updated
- 2019-02-07
- Results posted
- 2019-02-07
Locations
12 sites across 8 countries: Australia, Belgium, Denmark, France, Netherlands, New Zealand, Poland, Switzerland
Source: ClinicalTrials.gov record NCT00856856. Inclusion in this directory is not an endorsement.